SEC Form 4 · accession 0001209191-19-012708
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A. DesJardin
Officer — EVP, Technical Operations
Period of report
Feb 20, 2019
Accepted (ET)
Feb 22, 2019 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Feb 20, 2019 | A | 19,014 | $0.00 | A | 38,925 | D | |
| Ordinary Shares | Feb 20, 2019 | F | 9,429 | $21.54 | D | 29,496 | D | |
| Ordinary SharesF2 | Feb 21, 2019 | M | 2,182 | — | A | 31,678 | D | |
| Ordinary Shares | Feb 21, 2019 | F | 1,082 | $21.24 | D | 30,596 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2,F3 | — | Feb 21, 2019 | M | 2,182 | D | — | — | Ordinary Shares | 2,182 | 4,363 | D |
Explanation of responses
- F1On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met.
- F2Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F3On February 21, 2017, the reporting person was granted 8,726 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.